Evidence map›Paper›PMID 39451225›Full record

ArticleCells2024

Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital.

Nico Kraus, Frank Erhard Uschner, Magnus Moeslein, Robert Schierwagen, Wenyi Gu, Maximilian Joseph Brol, Eike Fürst, Inga Grünewald, Sophie Lotersztajn, Pierre-Emmanuel Rautou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nico KrausDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.ORCID 0000-0002-5162-1048
Frank Erhard UschnerDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Magnus MoesleinDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Robert SchierwagenDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.ORCID 0000-0002-2195-3666
Wenyi GuDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Maximilian Joseph BrolDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Eike FürstDepartment of Internal Medicine B, University Clinic Münster, 48149 Münster, Germany.
Inga GrünewaldGerhard-Domagk-Institute of Pathology, University Clinic Muenster, 48149 Münster, Germany.
Sophie LotersztajnCentre de Recherche sur L'inflammation, Université Paris-Cité, Inserm, UMR 1149, 45018 Paris, France.
Pierre-Emmanuel RautouCentre de Recherche sur L'inflammation, Université Paris-Cité, Inserm, UMR 1149, 45018 Paris, France.ORCID 0000-0001-9567-1859
Marta Duran-GüellDepartment of Biochemistry/Molecular Genetics, Hospital Clinic de Barcelona, IDIBAPS and CIBERehd, 08028 Barcelona, Spain.
Roger Flores CostaDepartment of Biochemistry/Molecular Genetics, Hospital Clinic de Barcelona, IDIBAPS and CIBERehd, 08028 Barcelona, Spain.
Joan ClàriaDepartment of Biochemistry/Molecular Genetics, Hospital Clinic de Barcelona, IDIBAPS and CIBERehd, 08028 Barcelona, Spain.ORCID 0000-0003-4333-7749
Jonel TrebickaDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.
Sabine KleinDepartment of Internal Medicine I, Hospital of the Goethe University, 60596 Frankfurt, Germany.ORCID 0000-0001-6691-2895
DECISION

Funding

Agence Nationale pour la Recherche ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, ANR-22-CE14-0002ANR-IMAGINE ANR-20- CE14-0038BMBF DEEP-HCCDECISION 847949DFG 403224013European Union's Horizon 2020 research and innovation programme 847949Eurostars 12350Fondation pour la Recherche Médicale Equipe FRM EQU202203014642Fondation pour la Recherche Médicale FRM EQU202303016287GALAXY 668031HMWK ENABLE, ACLF-IIHMCSA 964590Institut National de la Santé et de la Recherche Médicale ATIP AVENIRLIVERHOPE 731875MICROB-PREDICT 825694Ministerio de Ciencia e Innovacion/Agencia Estatal Investigación MCIN/AEI, PID2022-138970OB-I00 10.13039/501100011033/FEDER
6 · The paper itself

Abstract

Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl

Indexed as

Carbon TetrachlorideDisease Models, AnimalLiver CirrhosisPhenobarbitalAnimalsDiet, High-FatFatty LiverLiverMaleRatsCarbon TetrachloridePhenobarbitalcarbon tetrachloride (CCl4)high-fat and high-cholesterol Western diet (WD)long-term (LT)metabolic dysfunction-associated steatohepatitis (MASH)phenobarbital (PB)short-term (ST)

Identifiers

PMID39451225
PMCPMC11505720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.